Astrotech narrows quarterly net loss to $2.95M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Astrotech Corporation (ASTC) reported a net loss of $2.948 million for the quarter ended September 30, 2026, compared with $3.465 million a year earlier. Revenue fell 8% to $274,000 from $297,000; gross profit was $102,000 versus $188,000, and gross margin was 37% versus 63%. Operating expenses declined to $3.141 million from $3.724 million. Astrotech attributed the revenue decrease primarily to lower contract revenue and the absence of prior-year training revenue, partly offset by sales of three units and higher warranty and consumables revenue.
At quarter-end, cash and cash equivalents were $5.615 million, short-term investments were $2.856 million, and working capital was approximately $11.6 million. Operating activities used $3.194 million in cash, versus $3.936 million a year earlier. Under its ATM agreement, Astrotech sold 90,000 shares for approximately $467,000 in net proceeds during the quarter. Management believes cash, investments and operating cash flows will fund current operating plans and anticipated obligations for at least the next 12 months; it also said substantial additional capital may be required for longer-term growth and that available funds are insufficient to complete its business plan and strategic objectives.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNet loss narrowed to $2.948 million from $3.465 million year over year.
- Moderate pointOperating cash use declined to $3.194 million from $3.936 million.
Negative
- Moderate pointRevenue fell 8% to $274,000 year over year.
- Moderate pointGross margin fell to 37% from 63%.
Filing Explained
Astrotech’s ATM transaction for the quarter ended
Key Figures
Key Terms
at-the-market offering agreement financial
Baby Shelf Limitation regulatory
performance obligations financial
anti-dilutive financial
valuation allowance financial
fair value hierarchy financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did ASTC revenue decline in the September 2026 quarter?
How large is ASTC's ATM agreement?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
| | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
or
| | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ___________ to ___________
Commission file number

Astrotech Corporation
(Exact Name of Registrant as Specified in its Charter)
| | | |
| State or Other Jurisdiction of Incorporation or Organization | I.R.S. Employer Identification No. | |
| | | |
| Address of Principal Executive Offices | Zip Code |
(
Registrant’s Telephone Number, Including Area Code
Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| | | |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| | ☒ | Smaller reporting company | | |||
| Emerging growth company | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes
As of November 11, 2026, the number of shares of the registrant’s common stock issued and outstanding was
ASTROTECH CORPORATION AND SUBSIDIARIES
QUARTERLY REPORT ON FORM 10-Q
TABLE OF CONTENTS
| Page |
||
| PART I: |
FINANCIAL INFORMATION |
3 |
| ITEM 1. |
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) |
3 |
| ITEM 2. |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
20 |
| ITEM 3. |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
25 |
| ITEM 4. |
CONTROLS AND PROCEDURES |
25 |
| PART II: |
OTHER INFORMATION |
26 |
| ITEM 1. |
LEGAL PROCEEDINGS |
26 |
| ITEM 1A. |
RISK FACTORS |
26 |
| ITEM 2. |
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
27 |
| ITEM 3. |
DEFAULTS UPON SENIOR SECURITIES |
27 |
| ITEM 4. |
MINE SAFETY DISCLOSURES |
27 |
| ITEM 5. |
OTHER INFORMATION |
27 |
| ITEM 6. |
EXHIBITS |
28 |
PART I: FINANCIAL INFORMATION
ITEM 1. Condensed Consolidated Financial Statements
ASTROTECH CORPORATION AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| September 30, | June 30, | |||||||
| 2026 | 2026 | |||||||
| (Unaudited) | (Audited) | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Short-term investments | ||||||||
| Accounts receivable | ||||||||
| Inventory, net: | ||||||||
| Raw materials | ||||||||
| Work-in-process | ||||||||
| Finished goods | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Property and equipment, net | ||||||||
| Intangible asset, net | ||||||||
| Operating lease right-of-use assets, net | ||||||||
| Other assets, net | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | $ | ||||||
| Payroll related accruals | ||||||||
| Accrued expenses and other liabilities | ||||||||
| Lease liabilities, current | ||||||||
| Total current liabilities | ||||||||
| Accrued expenses and other liabilities, net of current portion | ||||||||
| Lease liabilities, net of current portion | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Note 15) | ||||||||
| Stockholders’ equity | ||||||||
| Common stock, $0.001 par value, 250,000,000 shares authorized at September 30, 2026, and June 30, 2026, respectively; 2,118,891 shares issued at September 30, 2026 and 2,009,050 shares issued at June 30, 2026, respectively; 2,108,575 and 1,998,734 shares outstanding at September 30, 2026 and June 30, 2026, respectively | ||||||||
| Treasury shares, 10,316 at September 30, 2026, and June 30, 2026, respectively | ( | ) | ( | ) | ||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Accumulated other comprehensive loss | ( | ) | ( | ) | ||||
| Total stockholders’ equity | ||||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||
See accompanying notes to unaudited condensed consolidated financial statements.
ASTROTECH CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share data)
(Unaudited)
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Revenue | $ | $ | ||||||
| Cost of revenue | ||||||||
| Gross profit | ||||||||
| Operating expenses: | ||||||||
| Selling, general and administrative | ||||||||
| Research and development | ||||||||
| Total operating expenses | ||||||||
| Loss from operations | ( | ) | ( | ) | ||||
| Other income and (expense), net | ||||||||
| Loss from operations before income taxes | ( | ) | ( | ) | ||||
| Income tax expense | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Weighted average common shares outstanding: | ||||||||
| Basic and diluted | ||||||||
| Basic and diluted net loss per common share: | ||||||||
| Net loss per common share | $ | ( | ) | $ | ( | ) | ||
| Other comprehensive loss, net of tax: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Available-for-sale securities: | ||||||||
| Net unrealized gain (loss) | ( | ) | ||||||
| Total comprehensive loss | $ | ( | ) | $ | ( | ) | ||
See accompanying notes to unaudited condensed consolidated financial statements.
ASTROTECH CORPORATION
Condensed Consolidated Statement of Changes in Stockholders’ Equity
(In thousands)
(Unaudited)
| Preferred Stock | ||||||||||||||||||||||||||||||||||||
| Series D | Common Stock | |||||||||||||||||||||||||||||||||||
| Number of Shares Outstanding | Amount | Number of Shares Outstanding | Amount | Treasury Stock Amount | Additional Paid-In Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Total Stockholders’ Equity | ||||||||||||||||||||||||||||
| Balance at June 30, 2026 | $ | $ | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||||||||
| Net change in available-for-sale marketable securities | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
| ATM Share issuance | ||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | 18 | ||||||||||||||||||||||||||||||||||
| Exercise of stock options | ||||||||||||||||||||||||||||||||||||
| Net loss | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
| Balance at September 30, 2026 | $ | $ | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||||||||
| Preferred Stock | ||||||||||||||||||||||||||||||||||||
| Series D | Common Stock | |||||||||||||||||||||||||||||||||||
| Number of Shares Outstanding | Amount | Number of Shares Outstanding | Amount | Treasury Stock Amount | Additional Paid-In Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Total Stockholders’ Equity | ||||||||||||||||||||||||||||
| Balance at June 30, 2025 | $ | $ | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||||||||
| Net change in available-for-sale marketable securities | — | — | ||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | ||||||||||||||||||||||||||||||||||
| Issuance of restricted stock | — | |||||||||||||||||||||||||||||||||||
| Net loss | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||||||||||
See accompanying notes to unaudited condensed consolidated financial statements.
ASTROTECH CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation | ||||||||
| Depreciation and amortization | ||||||||
| Amortization of operating lease right-of-use assets | ||||||||
| Interest on financing leases | ||||||||
| Changes in assets and liabilities: | ||||||||
| Accounts receivable | ||||||||
| Inventory, net | ( | ) | ( | ) | ||||
| Accounts payable | ( | ) | ( | ) | ||||
| Deferred revenue | ( | ) | ( | ) | ||||
| Other assets and liabilities | ( | ) | ( | ) | ||||
| Operating lease liabilities | ( | ) | ( | ) | ||||
| Net cash (used in) operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | ( | ) | ( | ) | ||||
| Proceeds from short-term investments | ||||||||
| Net cash provided by (used in) investing activities | ( | ) | ||||||
| Cash flows from financing activities: | ||||||||
| Repayment of financing liability in connection with internal-use software | ( | ) | ( | ) | ||||
| Repayments on finance lease liabilities | ( | ) | ( | ) | ||||
| Proceeds from at the market (ATM) share issuance | ||||||||
| Proceeds from exercise of stock options | ||||||||
| Net cash provided by (used in) financing activities | ( | ) | ||||||
| Net change in cash and cash equivalents | $ | ( | ) | $ | ( | ) | ||
| Cash and cash equivalents at beginning of period | ||||||||
| Cash and cash equivalents at end of period | $ | $ | ||||||
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Income taxes paid | ||||||||
| Non-cash financing activities: Finance lease expenditures incurred but not paid for as of the end of the period | $ | |||||||
See accompanying notes to unaudited condensed consolidated financial statements.
ASTROTECH CORPORATION AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(1) General Information
Business Overview
The terms “Astrotech”, “the Company”, “we”, “us”, or “our” refer to Astrotech Corporation (Nasdaq: ASTC), a Delaware corporation organized in 1984.
Our mission is to expand access to mass spectrometry (“MS”) and its use through the deployment of devices designed specifically for the appropriate levels of precision required in high-volume, real-time testing environments such as airports, border checkpoints, cargo hubs, infrastructure security, correctional facilities, military bases, law enforcement centers, and industrial locations. The Astrotech Mass Spectrometer Technology™ (“AMS Technology”) platform achieves our mission through simplifying the user interface, automating the complicated calibration process, ruggedizing the critical components to endure MS field work, and enabling multiple configurations for sample intake options.
We are commercializing the AMS Technology through application specific, wholly owned subsidiaries described below.
| ● | Astrotech Technologies, Inc. (“ATI”) owns and licenses the intellectual property related to the AMS Technology. |
| ● | 1st Detect Corporation (“1st Detect”) is a manufacturer of explosives trace detectors (“ETDs”) and narcotics trace detectors (“NTDs”) developed for use in security and detection at airports, border checkpoints, cargo hubs, infrastructure security, correctional facilities, military bases, and law enforcement centers. 1st Detect holds an exclusive AMS Technology license from ATI for air passenger and cargo security applications as well as narcotics detection. |
| ● | AgLAB, Inc. (“AgLAB”) is developing a series of mass spectrometers for use in the hemp and cannabis market with initial focus on optimizing yields in the distillation processes. AgLAB holds an exclusive AMS Technology license from ATI for applications in the agriculture industry which require analyzing complex chemical compounds found in organic plant material and extracts. |
| ● | BreathTech Corporation (“BreathTech”) has developed the BreathTest-1000TM, a breath analysis tool designed to screen for volatile organic compound (“VOC”) metabolites found in a person’s breath that could indicate a compromised condition including but not limited to a bacterial or viral infection. BreathTech holds an exclusive AMS Technology license from ATI for breath analysis applications. Because commercialization of this application would require many years and significant investment due to regulatory requirements, the Company has determined to deploy capital instead to its other subsidiaries. |
| ● | Pro-Control, Inc. ("Pro-Control") is focused on applying the AMS Technology in industrial process control applications. The mass spectrometer and process are designed to test, measure and increase reaction intermediates, purity and percent yields in industrial processes. Pro-Control holds an exclusive AMS Technology license from ATI for the distillation of chemicals outside of the agriculture industry. |
| ● | EN-SCAN, Inc. (“EN-SCAN”) develops, manufactures and sells advanced environmental testing and monitoring solutions built around rugged, portable gas chromatography-based systems, including the EN-SCAN Handheld GC, EN-SCAN Fenceline Monitor, EN-SCAN Rugged Lab GC-MS, and the Labrador HH-GC, which was commercially launched in May 2026. EN-SCAN's current platform integrates a proprietary micro-electro-mechanical ("MEMs") pre-concentrator, a MEMS micro gas chromatographic column, and a photoionization detector to provide rapid, on-site detection of volatile organic compounds, and EN-SCAN plans to incorporate mass spectrometry into future product generations. EN-SCAN’s products are expected to support industrial, environmental, and regulatory applications, helping organizations meet compliance requirements and environmental safety. EN-SCAN uses proprietary ATi Gas Chromatograph (“GC”) and AMS Technology license from ATI for instant feedback to accurately detect soil, water, and air contamination source location and migration. |
| ● | Lunar Utilities Corporation (“LUC”) is a recently approved strategic initiative focused on future lunar resource development, autonomous lunar industrial infrastructure, Moon-based advanced computing, semiconductor, manufacturing, lunar power generation and power infrastructure, mining, chemical manufacturing, product transportation and equipment leasing opportunities on the Moon. As part of the initiative, Astrotech intends to evaluate and potentially develop infrastructure technologies that could support semiconductor processing, advanced computing systems, and quantum computing manufacturing operations on the lunar surface. |
Principles of Consolidation and Basis of Presentation
The accompanying Unaudited Condensed Consolidated Financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles ("U.S. GAAP") for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the Unaudited Condensed Consolidated Financial Statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the Unaudited Condensed Consolidated Financial Statements included herin contain all adjustments necessary to fairly present our financial position, results of operations, and cash flows for the periods indicated. Adjustments included herein are of a normal, recurring nature unless otherwise disclosed in the Notes to the Unaudited Condensed Consolidated Financial Statements. The results for the interim period are not necessarily indicative of the results that may be expected for a full year. All intercompany balances and transactions have been eliminated. Amounts presented in this Form 10-Q may not sum due to rounding.
For additional information, refer to the Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2026 (the "2026 Annual Report on Form 10-K"), filed with the United States Securities and Exchange Commission (the "SEC").
Segment Information
The accounting guidance on Segment Reporting establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information of those segments to be presented in financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker (the “CODM”), the Chief Executive Officer, in making decisions on how to allocate resources and assess performance. The Company operates as
| Three Months Ended | ||||||||
| Revenue by Geographic Area | September 30, 2026 | September 30, 2025 | ||||||
| (In thousands) | ||||||||
| United States | $ | |||||||
| Foreign Countries | ||||||||
| Total Revenue | $ | $ | ||||||
| Revenue by Product | Three Months Ended | |||||||
| (In thousands) | September 30, 2026 | September 30, 2025 | ||||||
| Product Revenue | $ | $ | ||||||
| Training Revenue | ||||||||
| Contract Revenue | ||||||||
| Service Revenue | ||||||||
| Warranty Revenue | ||||||||
| Consumables Revenue | ||||||||
| Total Revenue | $ | $ | ||||||
Accounting Pronouncements
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” which is intended to enhance the transparency and decision usefulness of income tax disclosures. The guidance addresses investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. The guidance is effective for annual periods beginning after December 15, 2024. We adopted this standard in fiscal year ended June 30, 2026. This pronouncement has not impacted the Company’s consolidated financial statements.
In November 2024, the FASB also issued ASU 2024-04 “Debt - Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments” to clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. Under the amendments, to account for a settlement of a convertible debt instrument as an induced conversion, an inducement offer is required to provide the debt holder with, at a minimum, the consideration (in form and amount) issuable under the conversion privileges provided in the terms of the instrument. An entity should assess whether this criterion is satisfied as of the date the inducement offer is accepted by the holder. If, when applying this criterion, the convertible debt instrument had been exchanged or modified (without being deemed substantially different) within the one-year period leading up to the offer acceptance date, an entity should compare the terms provided in the inducement offer with the terms that existed one year before the offer acceptance date. The amendments in this update also clarify that the induced conversion guidance applies to a convertible debt instrument that is not currently convertible as long as it had a substantive conversion feature as of both its issuance date and the date the inducement offer is accepted. The company adopted ASU 2024-04 effective July 1, 2026. The adoption of this guidance did not have any material impact on the Company's consolidated financial statements.
Recently Issued Accounting Standards Not Yet Adopted
In November 2024, the FASB issued Accounting Standards Update 2024-03 "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)" which requires that at each interim and annual reporting period an entity:
1. Disclose the amounts of (a) purchases of inventory, (b) employee compensation, (c) depreciation, (d) intangible asset amortization, and (e) depreciation, depletion, and amortization included in each relevant expense caption. A relevant expense caption is an expense caption presented on the face of the income statement within continuing operations that contains any of the listed expense categories.
2. Include certain amounts that are already required to be disclosed under GAAP in the same disclosure as the other disaggregation requirements.
3. Disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively.
4. Disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses.
These amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027: either (1) prospectively to financial statements issued for reporting periods after the effective date of this update or (2) retrospectively to any or all prior periods presented in the financial statements. The Company expects to enhance disclosures of expenses based on new requirements.
Other accounting pronouncements issued but not yet effective are not believed by management to be relevant or to have a material impact on the Company’s present or future consolidated financial statements.
(2) Liquidity
The Company had cash of approximately $
Substantial additional capital will be required to support longer-term growth and operational objectives. Future cash flows are subject to a number of variables, including the ability to generate sales under existing and future business opportunities, and significant additional capital expenditures may be required to conduct our operations. There can be no assurance that operations and other capital sources will provide sufficient cash to maintain planned or future levels of capital expenditures.
We regularly monitor potential financings and capital sources, including equity and debt markets, in an effort to meet our planned capital expenditures and liquidity requirements. The availability and terms of future financing will depend on a variety of factors, including general economic and market conditions, our operating performance, and investor interest. Additional funding may not be available on acceptable terms, if at all. If we are unable to obtain adequate financing when needed, we may be forced to delay, reduce the scope of, or eliminate certain operations, commercialization efforts, or other aspects of our business. In addition, raising additional funds through equity offerings may result in dilution to our stockholders, while debt or other financing could involve covenants or obligations that restrict our business operations. Until we can generate sufficient revenue from product sales, if at all, we expect to finance our operations primarily through existing cash reserves and additional capital-raising activities.
(3) Investments
The following tables summarize gains and losses related to the Company’s investments as of September 30, 2026, and June 30, 2026, respectively:
| September 30, 2026 | ||||||||||||||||
| Available-for-Sale Investments | Adjusted | Unrealized | Unrealized | Fair | ||||||||||||
| (In thousands) | Cost | Gain | Loss | Value | ||||||||||||
| Mutual Funds - Corporate & Government Debt | $ | $ | $ | ( | ) | $ | ||||||||||
| Total | $ | $ | $ | ( | ) | $ | ||||||||||
| June 30, 2026 | ||||||||||||||||
| Available-for-Sale Investments | Adjusted | Unrealized | Unrealized | Fair | ||||||||||||
| (In thousands) | Cost | Gain | Loss | Value | ||||||||||||
| Mutual Funds - Corporate & Government Debt | $ | $ | $ | ( | ) | $ | ||||||||||
| Total | $ | $ | $ | ( | ) | $ | ||||||||||
All investments were classified as short-term investments as of September 30, 2026 and June 30, 2026. For more information about the fair value of the Company’s financial instruments, see Note 11.
The following table presents the carrying amounts of certain financial instruments as of September 30, 2026, and June 30, 2026, respectively:
| Carrying Value | Carrying Value | |||||||||||||||
| Short-Term Investments | Long-Term Investments | |||||||||||||||
| (In thousands) | September 30, 2026 | June 30, 2026 | September 30, 2026 | June 30, 2026 | ||||||||||||
| Money Market Funds | ||||||||||||||||
| Mutual Funds - Corporate & Government Debt | $ | $ | $ | $ | ||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
(4) Leases
Operating lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate in determining the present value of lease payments. Significant judgment is required when determining the Company’s incremental borrowing rate. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The amortization expense for financed lease assets totaled approximately $
On January 29, 2025, we entered into a lease agreement, beginning on July 1, 2025, for a facility of approximately
The balance sheet presentation of the Company’s operating and finance leases is as follows:
| (In thousands) | Classification on the Condensed Consolidated Balance Sheet | September 30, 2026 | June 30, 2026 | ||||||
| Assets: | |||||||||
| Operating lease assets | Operating leases, right-of-use assets, net | $ | $ | ||||||
| Financing lease assets | Property and equipment, net | $ | |||||||
| Total lease assets | $ | $ | |||||||
| Liabilities: | |||||||||
| Current: | |||||||||
| Operating lease obligations | Lease liabilities, current | $ | $ | ||||||
| Financing lease obligations | Lease liabilities, current | ||||||||
| Non-current: | |||||||||
| Operating lease obligations | Lease liabilities, non-current | ||||||||
| Financing lease obligations | Lease liabilities, non-current | ||||||||
| Total lease liabilities | $ | $ | |||||||
Future minimum lease payments as of September 30, 2026, under non-cancellable leases are as follows (in thousands):
| (In thousands) | ||||||||||||
| As of September 30, | Operating Leases | Financing Leases | Total | |||||||||
| 2027 | $ | $ | | $ | ||||||||
| 2028 | ||||||||||||
| 2029 | ||||||||||||
| 2030 | ||||||||||||
| 2031 | ||||||||||||
| Thereafter | ||||||||||||
| Total lease obligations | | | | |||||||||
| Less: imputed interest | ( | ) | ( | ) | ( | ) | ||||||
| Present value of net minimum lease obligations | ||||||||||||
| Less: lease liabilities - current | ( | ) | ( | ) | ( | ) | ||||||
| Lease liabilities - non-current | $ | $ | $ | |||||||||
Other information as of September 30, 2026, is as follows:
| Weighted-average remaining lease term (years): | ||||
| Operating leases | ||||
| Financing leases | ||||
| Weighted-average discount rate: | ||||
| Operating leases | % | |||
| Financing leases | % |
Cash payments for operating leases for the three months ended September 30, 2026, and 2025 were $
(5) Property and Equipment, net
As of September 30, 2026, and June 30, 2026, property and equipment, net consisted of the following, respectively:
| (In thousands) | September 30, 2026 | June 30, 2026 | ||||||
| Furniture, fixtures, equipment & leasehold improvements | $ | $ | ||||||
| Software | ||||||||
| Capital improvements in progress | ||||||||
| Gross property and equipment | ||||||||
| Accumulated depreciation and amortization | ( | ) | ( | ) | ||||
| Property and equipment, net | $ | $ | ||||||
Depreciation and amortization expense of property and equipment was $
(6) Intangible Assets, net
As of September 30, 2026, and June 30, 2026, intangible assets, net consisted of the following, respectively:
| (In thousands) | September 30, 2026 | June 30, 2026 | ||||||
| Indefinite-life intangible asset | $ | $ | ||||||
| Accumulated amortization | ||||||||
| Intangible Assets, net | $ | $ | ||||||
The intangible asset consists of a license from a national laboratory for technology used in gas chromatographic products.
(7) Warranty Reserve
Astrotech offers its customers warranties on its products. These warranties typically provide for repairs and maintenance of the products if problems arise during a specified period after original shipment. Concurrent with the sale of products, the Company records a provision for estimated warranty expenses with a corresponding increase in cost of goods sold. The Company periodically adjusts this provision based on historical experience and anticipated expenses. The Company charges actual warranty repair costs, including parts and labor, against this reserve as incurred. The current obligation for warranty provision is included in accrued expenses and other liabilities in the condensed consolidated balance sheets. The warranty reserve balance was $
(8) Stockholders’ Equity
Preferred Stock
The Company has issued
Common Stock
The Company has issued
During the three months ended September 30, 2026, the Company issued approximately
On November 22, 2022, the Company filed a third amendment (the “Amendment”) to the Company’s Certificate of Incorporation (as amended, the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a 1-for-
Rights Plan
On December 21, 2022, the Company’s board of directors adopted a limited duration stockholder rights plan (the “Rights Plan”) expiring December 20, 2023 and declared a dividend of
On December 18, 2023, the Company entered into Amendment No. 1 to Rights Agreement between the Company and Equiniti Trust Company, as Rights Agent, which extended the Final Expiration Date (as defined in the Rights Plan) to December 20, 2024. On December 12, 2024, the Company entered into Amendment No. 2 to the Rights Agreement between the Company and the Rights Agent, which extends the Final Expiration Date to December 20, 2025, unless the Final Expiration Date is further extended by the Company or the rights subject to the Rights Plan are earlier redeemed or exchanged by the Company in accordance with the terms of the Rights Plan. On December 12, 2025, the Company entered into Amendment No. 3 to the Rights Agreement with the Rights Agent, which extends the Final Expiration Date to December 20, 2026, unless the Final Expiration Date is further extended by the Company in accordance with the terms of the Rights Plan. All other terms and conditions of the Rights Plan remain unchanged.
Warrants
The Company had
Shelf Registration Statement
On January 28, 2026, the Company filed a Registration Statement on Form S-3 (Registration No. 333-293023) (the “Shelf Registration Statement”), declared effective on January 30, 2026 by the SEC, which includes a base prospectus that allows the Company to offer and sell, from time to time, in one or more offerings, common stock, preferred stock, debt securities, warrants, rights or units up to an aggregate public offering price of $
On June 2, 2026, we entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC (the “ATM Agreement”), pursuant to which we may offer and sell shares of our common stock having aggregate gross proceeds of up to $
(9) Net Loss per Share
Basic net loss per share is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed based on the weighted average number of common shares outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method and the if-converted method. Potentially dilutive common shares include outstanding stock options and share-based awards.
The following table reconciles the numerators and denominators used in the computations of both basic and diluted net loss per share:
| Three Months Ended | ||||||||
| September 30, | ||||||||
| (In thousands, except per share data) | 2026 | 2025 | ||||||
| Numerator: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Denominator: | ||||||||
| Denominator for basic and diluted net loss per share — weighted average common stock outstanding | ||||||||
| Basic and diluted net loss per common share: | ||||||||
| Net loss per common share | $ | ( | ) | $ | ( | ) | ||
All unvested restricted stock awards and convertible Series D Preferred Shares for the three months ended September 30, 2026, are not included in diluted net loss per share, as the impact to net loss per share would be anti-dilutive. Options to purchase
(10) Revenue Recognition
Astrotech recognizes revenue employing the generally accepted revenue recognition methodologies described under the provisions of ASC Topic 606 “Revenue from Contracts with Customers” (“Topic 606”). The methodology used is based on contract type and how products and services are provided. The guidelines of Topic 606 establish a five-step process to govern the recognition and reporting of revenue from contracts with customers. The five steps are: (i) identify the contract with a customer, (ii) identify the performance obligations within the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations within the contract, and (v) recognize revenue when or as the performance obligations are satisfied.
An additional factor is reasonable assurance of collectability. This necessitates deferral of all or a portion of revenue recognition until assurance of collection. For the three months ended September 30, 2026,
Revenue from product and services sales are recognized when control of the goods is transferred to the customer which generally occurs at a point in time typically upon shipment to the customer or completion of the service. This standard applies to all contracts with customers. Warranty obligations associated with the sale of our products are assurance-type warranties that are a guarantee of the product’s intended functionality and, therefore, do not represent a distinct performance obligation within the context of the contract. Warranty expense is included in cost of sales. For the three months ended September 30, 2026, approximately $
Contract Assets and Liabilities.
Revenue under long-term government contracts is recorded under the percentage of completion method. Revenue, billable under cost-plus-fixed-fee contracts, is recorded as costs are incurred and includes estimated earned fees in the proportion that costs incurred to date bear to total estimated costs. Costs include direct labor, direct materials, subcontractor costs and manufacturing and administrative overhead allowable under the contract. Selling, general and administrative expenses allowable under the terms of contracts are allocated per contract, depending on its direct labor and material proportion to total direct labor and material of all contracts. As contracts can extend over one or more accounting periods, revisions in earnings estimated during the course of work are reflected during the accounting period in which the facts become known. The Company does not generally provide an allowance for returns from our government customers because our customer agreements do not provide for a right of return.
Practical Expedients.
Product Sales.
The Company recognizes revenue from sales of products upon shipment or delivery when control of the product transfers to the customer, depending on the terms of each sale, and when collection is probable. In the circumstance where terms of a product sale include subjective customer acceptance criteria, revenue is deferred until the Company has achieved the acceptance criteria unless the customer acceptance criteria are perfunctory or inconsequential. The Company generally offers customers payment terms of 60 days or less.
Freight.
The Company records shipping and handling fees that it charges to its customers as revenue and related costs as cost of revenue.
Multiple Performance Obligations.
Certain agreements with customers include the sale of equipment involving multiple elements in cases where obligations in a contract are distinct and thus require separation into multiple performance obligations, revenue recognition guidance requires that contract consideration be allocated to each distinct performance obligation based on its relative standalone selling price. The value allocated to each performance obligation is then recognized as revenue when the revenue recognition criteria for each distinct promise or bundle of promises has been met.
The standalone selling price for each performance obligation is an amount that depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the good or service. When there is only one performance obligation associated with a contract, the entire amount of consideration is attributed to that obligation. When a contract contains multiple performance obligations, the standalone selling price is first estimated using the observable price, which is generally a list price net of an applicable discount, or the price used to sell the good or service in similar circumstances. In circumstances when a selling price is not directly observable, the Company will estimate the standalone selling price using information available to it including its market assessment and expected cost, plus margin.
The timetable for fulfillment of each of the distinct performance obligations can range from completion in a short amount of time and entirely within a single reporting period to completion over several reporting periods. The timing of revenue recognition for each performance obligation may be dependent upon several milestones, including physical delivery of equipment, completion of site acceptance test, and in the case of after-market consumables and service deliverables, the passage of time.
(11) Fair Value Measurement
ASC Topic 820 “Fair Value Measurement” (“Topic 820”) defines fair value, establishes a market-based framework or hierarchy for measuring fair value, and expands disclosures about fair value measurements. Topic 820 is applicable whenever assets and liabilities are measured and included in the financial statements at fair value. The fair value hierarchy established in Topic 820 prioritizes the inputs used in valuation techniques into three levels as follows:
Level 1 - Quoted prices in active markets for identical assets or liabilities.
Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 - Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.
The following tables present the carrying amounts, estimated fair values, and valuation input levels of certain financial instruments as of September 30, 2026, and June 30, 2026:
| September 30, 2026 | ||||||||||||||||||||
| Carrying | Fair Value Measured Using | Fair | ||||||||||||||||||
| (In thousands) | Amount | Level 1 | Level 2 | Level 3 | Value | |||||||||||||||
| Available-for-Sale Investments | ||||||||||||||||||||
| Short-Term Investments | ||||||||||||||||||||
| Mutual Funds - Corporate & Government Debt | ||||||||||||||||||||
| Total Available-for-Sale Investments | $ | $ | $ | $ | $ | |||||||||||||||
| June 30, 2026 | ||||||||||||||||||||
| Carrying | Fair Value Measured Using | Fair | ||||||||||||||||||
| (In thousands) | Amount | Level 1 | Level 2 | Level 3 | Value | |||||||||||||||
| Available-for-Sale Investments | ||||||||||||||||||||
| Short-Term Investments | ||||||||||||||||||||
| Mutual Funds - Corporate & Government Debt | ||||||||||||||||||||
| Total Available-for-Sale Investments | $ | $ | $ | $ | $ | |||||||||||||||
The value of available-for-sale securities with Level 1 inputs is based on pricing from third-party pricing vendors, who use quoted prices in active markets for identical assets.
The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, short-term investments, accounts receivable, accounts payable, and accrued expenses and other liabilities at fair value or cost, which approximates fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.
As of the unaudited condensed consolidated balance sheets date, certain investment securities are required to be recorded at fair value with the change in fair value during the period being recorded as an unrealized gain or loss.
(12) Business Risk and Credit Risk Concentration Involving Cash
For the three months ended September 30, 2026 and 2025,
The Company maintains funds in bank accounts that may exceed the limit insured by the Federal Deposit Insurance Corporation (“FDIC”). The risk of loss attributable to these uninsured balances is mitigated by depositing funds in what the Company believes to be high-credit-quality financial institutions. The Company has not experienced any losses in such accounts. The general insurance limit is $250,000 per separately insured depositor. The combined balances of these bank accounts as of September 30, 2026, were approximately $
(13) Stock-Based Compensation
We have granted equity incentives to employees and directors in the form of stock options and restricted stock awards. The total stock-based compensation expense for all equity incentives was $
Stock Options
The Company’s stock option activity for the three months ended September 30, 2026, is as follows:
| Shares | Weighted Average Exercise Price | |||||||
| Outstanding at June 30, 2026 | $ | |||||||
| Granted | ||||||||
| Exercised | ( | ) | ||||||
| Canceled or expired | ( | ) | ||||||
| Outstanding at September 30, 2026 | $ | |||||||
The aggregate intrinsic value was $
The table below details the Company’s stock options outstanding as of September 30, 2026:
| Range of Exercise prices | Number Outstanding | Options Outstanding Weighted-Average Remaining Contractual Life (Years) | Weighted-Average Exercise Price | Number Exercisable | Options Exercisable Weighted-Average Exercise Price | |||||||||||||||||
| $ | $ | $ | ||||||||||||||||||||
| $ | ||||||||||||||||||||||
| $ | ||||||||||||||||||||||
| $ | ||||||||||||||||||||||
| $ | $ | $ | ||||||||||||||||||||
Compensation costs recognized related to stock option awards were $
Restricted Stock
The Company’s restricted stock activity for the three months ended September 30, 2026, is as follows:
| Shares | Weighted Average Grant Date Fair Value | |||||||
| Outstanding at June 30, 2026 | $ | |||||||
| Granted | ||||||||
| Vested | ( | ) | ||||||
| Adjustment Winn Grant 12/24 | ||||||||
| Canceled or expired | ||||||||
| Outstanding at September 30, 2026 | $ | |||||||
Stock compensation expenses related to restricted stock were $
(14) Income Taxes
The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are more likely than not to be realized. As of September 30, 2026, the Company has a valuation allowance against all of its net deferred tax assets.
For the three months ended September 30, 2026 and 2025, the Company incurred pre-tax losses in the amount of $
For each of the three months ended September 30, 2026 and 2025, the Company’s effective tax rate differed from the federal statutory rate of
FASB ASC 740, “Income Taxes” addresses the accounting for uncertainty in income tax recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken on a tax return. The Company currently has approximately $
Loss carryovers are generally subject to modification by tax authorities until three years after they have been utilized; as such, the Company is subject to examination for the fiscal years ended 2001 through present for federal purposes and fiscal years ended 2006 through present for state purposes.
(15) Commitments and Contingencies
From time to time, the Company is subject to legal and administrative proceedings, settlements, investigations, claims and actions. The Company’s assessment of the likely outcome of litigation matters is based on its judgment of several factors including experience with similar matters, history, precedents, relevant financial and other evidence and facts specific to the matter. Notwithstanding the uncertainty as to the outcome, based upon the information currently available, management does not believe any matters, individually or in aggregate, will have a material adverse effect on the Company’s financial position or results of operations.
The Company establishes reserves for the estimated losses on specific contingent liabilities, for regulatory and legal actions where the Company deems a loss to be probable and the amount of the loss can be reasonably estimated. In other instances, the Company is not able to make a reasonable estimate of liability because of the uncertainties related to the outcome or the amount or range of potential loss.
(16) Subsequent Events
Management has determined there are no subsequent events to report through November 13, 2026
(17)
Related Party
During the three months ended September 30, 2026, the Company has incurred consulting expenses of $
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements for purposes of federal and state securities laws. Forward-looking statements may include the words “may,” “will,” “plans,” “believes,” “estimates,” “expects,” “intends,” and other similar expressions. Such statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected in the statements. Such risks and uncertainties include, but are not limited to:
| ● | Our strategic initiatives focused on future lunar resource development, autonomous lunar industrial infrastructure, Moon-based advanced computing, semiconductor manufacturing, lunar power generation and power infrastructure, mining, chemical manufacturing, product transportation and equipment leasing opportunities on the moon; |
| ● | The success of the potential sale of 1st Detect, and the risks the announcement and pendency of the proposed sale present to our going business and operations; |
| ● |
The adverse expectations regarding the global economy, inflation, the potential for recession and geopolitical tensions and any resulting sanctions, or wars; |
| ● |
The effect of economic and political conditions in the United States or other nations that could impact our ability to sell our products and services or gain customers; |
| ● |
Product demand and market acceptance risks, including our ability to develop and sell products and services to be used by governmental or commercial customers; |
| ● |
The impact of trade barriers imposed by the U.S. government, such as import/export duties and restrictions, tariffs and quotas, and potential corresponding actions by other countries in which we conduct our business; |
| ● |
Technological difficulties and potential legal claims arising from any technological difficulties; |
| ● |
The risks related to the availability of, and cost inflation in, supply chain inputs, including labor, raw materials, commodities, packaging, and transportation; |
| ● |
Uncertainty in government funding and support for key programs, grant opportunities, or procurements; |
| ● |
The impact of competition on our ability to win new contracts; |
| ● |
Our ability to meet technological development milestones and overcome development challenges; and |
| ● |
Our ability to successfully identify, complete and integrate acquisitions. |
While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others identified herein.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
Although we believe that the assumptions underlying our forward-looking statements are reasonable, any of the assumptions could be inaccurate; therefore, we cannot assure you that the forward-looking statements included in this Quarterly Report on Form 10-Q will prove to be accurate. Considering the significant uncertainties inherent in our forward-looking statements, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Some of these and other risks and uncertainties that could cause actual results to differ materially from such forward-looking statements are more fully described in our Annual Report on Form 10-K for the fiscal year ended June 30, 2026 (the “2026 Form 10-K”), elsewhere in this Quarterly Report on Form 10-Q , or those discussed in other documents we filed with the SEC. Except as may be required by applicable law, we undertake no obligation to publicly update or advise of any change in any forward-looking statement, whether as a result of new information, future events, or otherwise. In making these statements, we disclaim any obligation to address or update each factor in future filings with the SEC or communications regarding our business or results, and we do not undertake to address how any of these factors may have caused changes to discussions or information contained in previous filings or communications. In addition, any of the matters discussed above may have affected our past results and may affect future results, so that our actual results may differ materially from those expressed in this Quarterly Report on Form 10-Q and in prior or subsequent communications.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following information should be read in conjunction with the unaudited condensed consolidated financial statements and the accompanying notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Business Overview
The terms “Astrotech”, “the Company”, “we”, “us”, or “our” refer to Astrotech Corporation (Nasdaq: ASTC), a Delaware corporation organized in 1984. Our use of “products” and “devices” refer to the TRACER 1000™, BreathTest-1000™, AGLAB 1000™, TRACER 1000™ NTD, Pro-Control 1000™, and EN-SCAN products, including the Labrador HH-GC along with related accessories and consumables.
Our mission encompasses the advancement of both mass spectrometry and gas chromatography, two powerful analytical techniques that together enable precise detection and identification of chemical compounds across a wide range of high-demand environments. We aim to expand access to mass spectrometry by simplifying the complexity of operating these devices within real-time testing environments such as airports, border checkpoints, cargo hubs, infrastructure security, correctional facilities, military bases, law enforcement centers, and industrial locations. We are introducing our new line of products that are ultra-portable, on-site, rugged environmental testing instruments, featuring our proprietary ATI MS and ATi GC to achieve our mission through simplifying the user interface, automating the complicated calibration process, ruggedizing the critical components to endure MS/GC field work, and enabling multiple configurations for sample intake options.
Astrotech Technologies, Inc.
ATI owns and licenses the AMS Technology, the platform MS technology originally developed by 1st Detect. The AMS Technology has been designed to be inexpensive, smaller, and easier to use when compared to traditional mass spectrometers. Unlike other technologies, the AMS Technology works under ultra-high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The intellectual property includes 17 patents granted along with extensive trade secrets. With a number of diverse market opportunities for the core technology, ATI is structured to license the intellectual property for different fields of use. ATI currently licenses the AMS Technology to five wholly-owned subsidiaries of Astrotech on an exclusive basis, including to 1st Detect for use in security and detection applications, to AgLAB for use in agriculture applications, to BreathTech for use in breath analysis applications, to Pro-Control for use in production applications, and to EN-SCAN for use in industrial and environmental applications
1st Detect Corporation
1st Detect, a licensee of ATI for security and detection applications, has developed the TRACER 1000, the world’s first MS based ETD certified by the ECAC and approved by TSA for air cargo. The TRACER 1000 was designed to outperform the ETDs currently used at airports, cargo and other secured facilities, and borders worldwide. We believe that ETD customers are unsatisfied with the currently deployed ETD technology, which is driven by ion mobility spectrometry (“IMS”). We further believe that some IMS-based ETDs have issues with false positives, as they often misidentify personal care products and other common household chemicals as explosives, causing facility shutdowns, unnecessary delays, frustration, and significant wasted security resources. In addition, there are hundreds of different types of explosives, but IMS-based ETDs have a very limited threat detection library reserved only for those few explosives of largest concern. Adding additional compounds to the detection library of an IMS-based ETD fundamentally reduces the instrument’s performance, further increasing the likelihood of false alarms. In contrast, adding additional compounds to the TRACER 1000’s detection library does not degrade its detection capabilities, as it has a virtually unlimited and easily expandable threat library.
AgLAB Inc.
AgLAB, an exclusive licensee of ATI for the use in the agriculture industry to analyze complex chemical compounds found in organic plant material and extracts, has developed the AgLAB 1000™ series of mass spectrometers for use in the hemp and cannabis markets with the initial focus on optimizing yields in the distillation process. The AgLAB product line is a derivative of our core AMS Technology. AgLAB continues to conduct field trials demonstrating that the AgLAB 1000-D2™ can be used in the distillation process to significantly improve the yields of tetrahydrocannabinol and cannabidiol oil during distillation. The AgLAB 1000-D2™ uses the Maximum Value Process solution to analyze samples in real-time and assist the equipment operator in determining the ideal operating settings required to maximize yields.
BreathTech Corporation
BreathTech, an exclusive licensee of ATI for use in breath analysis applications, was in the process of developing the BreathTest-1000™, a breath analysis tool to screen for VOC metabolites found in a person’s breath that could indicate a compromised medical condition.
Pro-Control, Inc.
Pro-Control, Inc. (“Pro-Control”) is an exclusive licensee with ATI to utilize its AMS Technology for industrial process control applications involving chemical distillation outside of the agriculture industry. Pro-Control uses advanced mass spectrometer instrumentation to monitor and control the production and operations of manufacturing processes using real-time, in-process samples. Pro-Control provides the vital spectral qualitative and quantitative data needed to control the production parameters (temperatures, flow, speed and pressure) while significantly improving efficiency.
Pro-Control has introduced its proprietary Pro-Control Maximum Value Processing and the Pro-Control 1000-D2™ mass spectrometer, which in combination are designed to test, measure and increase reaction intermediates, purity and percent yields in industrial processes.
EN-SCAN, Inc.
EN-SCAN, Inc. (“EN-SCAN”) develops, manufactures and sells advanced environmental testing and monitoring solutions built around rugged, portable gas chromatography-based systems, including the EN-SCAN Handheld GC, EN-SCAN Fenceline Monitor, EN-SCAN Rugged Lab GC-MS, and the Labrador HH-GC, which was commercially launched in May 2026. EN-SCAN plans to incorporate mass spectrometry into future product generations. EN-SCAN’s products support industrial, environmental, and regulatory applications, helping organizations meet compliance requirements and environmental safety. EN-SCAN uses proprietary ATi Gas Chromatograph and AMS Technology license from ATI for instant feedback to accurately detect soil, water, and air contamination source location and migration.
Lunar Utilities Corporation
On October 16, 2026, the Certificate of Incorporation was amended to change the corporation's name to Lunar Utilities (“LUC”). LUC is focused on potentially developing infrastructure technologies that could support semiconductor processing, advanced computing systems, and quantum computing manufacturing operations on the lunar surface.
Critical Accounting Estimates
The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with United States Generally Accepted Accounting Principles (“GAAP”). The preparation of these financial statements requires us to make estimates and judgments that directly affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosure of contingent assets and liabilities in our Company’s consolidated financial statements and accompanying notes. A critical accounting estimate is one that involves a significant level of estimation or uncertainty and has had or is reasonably likely to have a material impact on our financial condition or results of operations. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management continuously evaluates its critical accounting policies and estimates, including those used in evaluating the recoverability of long-lived assets, recognition of revenue, valuation of inventory, and the recognition and measurement of loss contingencies, if any. Actual results may differ from these estimates under different assumptions or conditions. We believe that the following accounting policies require us to make significant judgments and estimates in the preparation of our consolidated financial statements.
Results of Operations
Three months ended September 30, 2026, compared to three months ended September 30, 2025:
Selected consolidated financial data for the three months ended September 30, 2026, and 2025 is as follows:
| Three Months Ended September 30, |
||||||||
| (In thousands) |
2026 |
2025 |
||||||
| Revenue |
$ | 274 | $ | 297 | ||||
| Cost of revenue |
172 | 109 | ||||||
| Gross profit |
102 | 188 | ||||||
| Gross margin |
37 | % | 63 | % | ||||
| Operating expenses: |
||||||||
| Selling, general and administrative |
2,115 | 1,780 | ||||||
| Research and development |
1,026 | 1,944 | ||||||
| Total operating expenses |
3,141 | 3,724 | ||||||
| Loss from operations |
(3,039 | ) | (3,536 | ) | ||||
| Other income and expense, net |
91 | 71 | ||||||
| Net loss |
$ | (2,948 | ) | $ | (3,465 | ) | ||
Revenue – Total revenue decreased $23 thousand, or 8%, to $274 thousand for the three months ended September 30, 2026, compared to $297 thousand for the three months ended September 30, 2025. The decrease was primarily due to lower contract revenue of $127 thousand and the non-recurrence of $20 thousand of training revenue recognized in the prior-year period. These decreases were partially offset by $107 thousand of product revenue from the sale of three units, $9 thousand of higher warranty revenue, and $7 thousand of higher consumables revenue.
Cost of Revenue – Gross profit is comprised of revenue less cost of revenue. Cost of revenue includes materials, overhead, warranty expenses, shipping, and labor. Cost of revenue increased by $63 thousand during the three months ended September 30, 2026, compared to the same period in 2025. The increase was primarily driven by higher material costs of $67 thousand associated with the sale of three units during the current-year period. As a result, gross margin decreased to 37% for the three months ended September 30, 2026, compared to 63% for the same period in 2025.
Operating Expenses – Operating expenses decreased by $583 thousand, or 16%, during the three months ended September 30, 2026, compared to the same period in 2025. Significant changes to operating expenses include the following:
| ● |
Selling, general and administrative expenses increased $335 thousand, or 19%, to $2.1 million from $1.8 million for the three months ended September 30, 2026, compared to the same period in 2025. The increase primarily reflected higher consulting expenses of $371 thousand, including a $200 thousand marketing-services engagement and fees for an interim Chief Financial Officer ("CFO") following the departure of the former CFO; higher facilities expenses of $177 thousand, primarily due to the transfer of Braker facility lease-related costs from research and development to selling, general and administrative expenses; and higher accounting and compliance expenses of $79 thousand. These increases were partially offset by a $245 thousand decrease in employee compensation and related costs resulting from lower headcount, including the former CFO position, and a $188 thousand decrease in legal expenses, primarily reflecting the reclassification of offering-related costs to additional paid-in capital. |
| ● |
Research and development expenses decreased $918 thousand, or 47%, to $1.0 million from $1.9 million during the three months ended September 30, 2026, compared with the same period in 2025. The decrease primarily reflected lower employee compensation and related costs of $379 thousand following research and development headcount reductions and the reclassification of certain labor costs to cost of revenue, including labor associated with manufacturing activities and percentage-of-completion contract work, lower contractor and consultant expense of $320 thousand, including a $60 thousand consultant retainer transferred to selling, general and administrative expenses; and lower facilities expense of $149 thousand following the transfer of Braker facility lease-related costs to selling, general and administrative expenses. The decrease also reflected lower depreciation expense of $50 thousand, the absence of $47 thousand of recruiting expense incurred in the prior-year period, and the reclassification of $20 thousand of insurance expense to selling, general and administrative expense. These decreases were partially offset by a $92 thousand increase in materials and equipment expenses, primarily reflecting higher inventory impairment charges on aged inventory. |
Other Income and Expense, net – Other income and expense, net increased $20 thousand during the three months ended September 30, 2026, compared to the same period in 2025. The increase primarily reflected the absence of a realized loss on securities recognized in the prior year period, partially offset by lower dividend income due to reduced investment balances.
Liquidity and Capital Resources
Cash Flows
The following is a summary of the change in our cash and cash equivalents:
| Three Months Ended September 30, |
||||||||||||
| (In thousands) |
2026 |
2025 |
Change |
|||||||||
| Change in cash and cash equivalents: |
||||||||||||
| Net cash provided by (used in) operating activities |
$ | (3,194 | ) | $ | (3,936 | ) | $ | 742 | ||||
| Net cash provided by (used in) investing activities |
(26 | ) | 3,518 | (3,544 | ) | |||||||
| Net cash provided by (used in) in financing activities |
448 | (36 | ) | 484 | ||||||||
| Net change in cash and cash equivalents |
$ | (2,772 | ) | $ | (454 | ) | $ | (2,318 | ) | |||
Cash and Cash Equivalents
As of September 30, 2026, cash was $5.6 million, short-term investments were $2.9 million, and working capital was $11.6 million. Cash decreased $2.8 million during the quarter, primarily from operating cash use, partially offset by financing proceeds.
Operating Activities
Cash used in operating activities was approximately $3.2 million for the three months ended September 30, 2026, compared with $3.9 million for the same period in 2025. Cash used in operating activities primarily reflected the Company's net loss of $2.9 million, partially offset by noncash charges of approximately $0.6 million, including stock-based compensation, depreciation and amortization, and amortization of right of use assets. Changes in working capital also used cash during the quarter, including a $273 thousand increase in prepaid expenses and other current assets, primarily related to prepaid insurance, a $116 thousand increase in inventory, a $121 thousand decrease in deferred revenue, primarily related to the recognition of previously deferred revenue, and a $286 thousand decrease in accounts payable and accrued liabilities.
Investing Activities
Cash used in investing activities was approximately $26 thousand for the three months ended September 30, 2026, compared to cash provided by investing activities of approximately $3.5 million for the three months ended September 30, 2025. For the three months ended September 30, 2026, investing activities consisted solely of purchases of property and equipment. The prior-year period included $4.0 million of proceeds from short-term investments, partially offset by $448 thousand of leasehold improvements associated with the Company's relocation to the Braker facility.
Financing Activities
Cash provided by financing activities was approximately $448 thousand for the three months ended September 30, 2026, compared with cash used in financing activities of approximately $36 thousand for the same period in 2025. Cash provided by financing activities during the current-year period consisted primarily of $467 thousand of net proceeds from the Company's at-the-market equity program and $8 thousand of proceeds from stock option exercises, partially offset by $21 thousand of repayments on financing obligations related to internal-use software and $6 thousand of finance lease principal payments.
We did not have any material off-balance sheet arrangements as of September 30, 2026.
LIQUIDITY AND CAPITAL RESOURCES
Liquidity
As of September 30, 2026, we had cash and cash equivalents of $5.6 million, short-term investments of $2.9 million, and had positive working capital of $11.6 million. We have incurred recurring losses and negative cash flows from operations since inception and had an accumulated deficit of approximately $268.2 million as of September 30, 2026, and reported a net loss of $2.9 million. We regularly monitor potential financing and capital sources, including equity and debt markets, in an effort to meet our planned capital expenditures and liquidity requirements. Our future success may depend on our ability to access outside sources of capital including through public or private equity offerings, additional debt financing, or via strategic collaborations, partnerships, or other arrangements with third parties. The availability and terms of future financing will depend on a variety of factors, including general economic and market conditions, our operating performance, and investor interest. Additional funding may not be available on acceptable terms, if at all. If we are unable to obtain adequate financing when needed, we may be forced to delay, reduce the scope of, or eliminate certain operations, commercialization efforts, or other aspects of our business. In addition, raising additional funds through equity offerings may result in dilution to our stockholders, while debt or other financing could involve covenants or obligations that restrict our business operations. Until we can generate sufficient revenue from product sales, if at all, we expect to finance our operations primarily through existing cash reserves and additional capital-raising activities.
We expect that our short-term and long-term liquidity requirements will consist of working capital and general corporate expenses associated with the growth of our business, including, without limitation, expenses associated with scaling up our operations and continuing to increase our manufacturing capacity, sales and marketing expense associated with rollout of our products to commercial customers, additional research and development expenses associated with expanding our product offerings, and expenses associated with being a public company. In addition, we expect that our strategic initiatives approved by our Board focused on future lunar resource development, autonomous lunar industrial infrastructure, Moon-based advanced computing, semiconductor manufacturing, lunar power generation and related opportunities (our “Lunar Initiatives“), which remain in the explorative planning and design stage and for which no formal business plan or capital budget has been approved, will require substantial capital expenditures to design, develop, expand, and maintain our technologies and infrastructure to support development of such initiatives, including costs associated with research and development, construction and expansion of production capabilities, acquisition of property and equipment, and ongoing maintenance and upgrades to ensure reliability and competitiveness. While management believes that our cash and cash equivalents and short-term investments as of September 30, 2026, together with operational cash flows will fund our current operating plans and meet our anticipated obligations for at least the next 12 months, substantial additional capital may be required to support longer-term growth and operational objectives. Our short-term investments have been utilized as a source of liquidity to fund our operating expenses.
On January 28, 2026, the Company filed a Registration Statement on Form S-3 (Registration No. 333-293023) (the “Shelf Registration Statement”), declared effective on January 30, 2026 by the SEC, which includes a base prospectus that allows the Company to offer and sell, from time to time, in one or more offerings, common stock, preferred stock, debt securities, warrants, rights or units up to an aggregate public offering price of $30 million. As described in the Shelf Registration Statement, pursuant to General Instruction I.B.6 of Form S-3, in no event will the Company sell securities registered on the Shelf Registration Statement, in a public primary offering with a value exceeding more than one-third of the Company's public float in any 12-month period so long as the Company's public float remains below $75 million (the “Baby Shelf Limitation”). The Shelf Registration Statement is intended to preserve the Company's flexibility to raise capital from time to time, if and when needed.
On June 2, 2026, we entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC (the “ATM Agreement”), pursuant to which we may offer and sell shares of our common stock having aggregate gross proceeds of up to $50.0 million, subject to applicable limitations, including General Instruction I.B.6 of Form S-3. Shares are offered under our shelf registration statement on Form S-3 (File No. 333-297144), declared effective on July 7, 2026. During the three months ended September 30, 2026, we sold 90,000 shares under the ATM Agreement for net proceeds of approximately $467 thousand, and as of September 30, 2026, approximately $42.1 million remained available under the ATM Agreement.
Management continues to monitor liquidity needs closely and will adapt strategy as appropriate to align with both near- and long-term business objectives. Management anticipates that significant additional expenditures will be necessary to develop and expand our business, before significant positive operating cash flows can be achieved, as current available funds are insufficient to complete our business plan and strategic objectives. Until we can generate sufficient revenue from sales, if at all, we expect to finance our operations primarily through existing cash reserves and additional capital-raising activities.
Income Taxes
Provision for Income Tax
The Company’s effective tax rate is 0% for income tax for the three months ended September 30, 2026 and the Company expects that its effective tax rate for the full fiscal year 2027 will be (0.05)%. Based on the weight of available evidence, including net cumulative losses and expected future losses, the Company has determined that it is more likely than not that its U.S. federal and state deferred tax assets will not be realized and therefore a full valuation allowance has been provided on the U.S. federal and state net deferred tax assets.
In general, if the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change net operating loss (NOL) carryforwards are subject to an annual limitation under Section 382 of the Internal Revenue Code. Generally, U.S. state laws have laws similar to Internal Revenue Code Section 382. The annual limitation generally is determined by multiplying the value of the Company’s stock at the time of such ownership change (subject to certain adjustments) by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforward before utilization.
The Company files U.S. federal and state income tax returns. The Company is not currently subject to any income tax examinations. The Company has net operating loss carryovers dating back to the June 2002 year, which generally allows all tax years to remain open to income tax examinations for all years for which there are loss carryforwards.
Uncertain Tax Positions
The Company recognizes the financial statement effects of a tax position when it becomes more likely than not, based upon the technical merits, that the position will be sustained upon examination. The Company currently has approximately $848 thousand of uncertain tax positions as of September 30, 2026, all of which are accounted for as contra-deferred tax assets. The Company does not expect any significant changes to its uncertain tax positions in the coming 12 months.
Income Taxes
There was no income tax expense during the three months ended September 30, 2026 or 2025.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable to smaller reporting companies.
ITEM 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including the CEO and CFO, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management was required to apply its judgment in evaluating and implementing possible controls and procedures. Management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2026, at the reasonable assurance level.
Changes in Internal Controls over Financial Reporting
There have been no changes in our internal controls over financial reporting that occurred during our last fiscal quarter ended September 30, 2026, that materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.
PART II: OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
From time to time, the Company is subject to legal and administrative proceedings, settlements, investigations, claims and actions. The Company’s assessment of the likely outcome of litigation matters is based on its judgment of several factors including experience with similar matters, history, precedents, relevant financial and other evidence and facts specific to the matter. Notwithstanding the uncertainty as to the outcome, based upon the information currently available, management does not believe any matters, individually or in aggregate, will have a material adverse effect on the Company’s financial position or results of operations.
ITEM 1A. RISK FACTORS
Our business, financial condition, results of operations, and cash flows may be impacted by several factors, many of which are beyond our control, including those set forth in Item 1A. “Risk Factors” of our 2026 Form 10-K, the occurrence of any one of which could have a material adverse effect on our actual results. There were no material changes to the risk factors disclosed in Item 1A. “Risk Factors” of our 2026 Form 10-K.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
During the three months ended September 30, 2026, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b501 trading arrangement," as each term is defined in Item 408 of Regulation S-K.
ITEM 6. EXHIBITS
| Exhibit No. |
Description |
Incorporation by Reference |
| 3.1 |
Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware. |
Exhibit 3.1 to Form 8-K filed on December 28, 2017. |
| 3.2 |
Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-K filed with the Securities and Exchange Commission on August 1, 2023). |
Exhibit 3.1 to Form 8-K filed on August 1, 2023. |
| 3.3 |
Certificate of Designations of Series A Junior Participating Preferred Stock, as filed with the Secretary of State of the State of Delaware. |
Exhibit 3.3 to Form 8-K filed on December 28, 2017. |
| 3.4 |
Certificate of Designations of Preferences, Rights and Limitations of Series D Convertible Preferred Stock, as filed with the Delaware Secretary of State on April 17, 2019. |
Exhibit 3.2 to Form 8-K filed on April 23, 2019. |
| 3.5 |
Certificate of Amendment to the Certificate of Incorporation of Astrotech Corporation. |
Exhibit 3.1 to Form 8-K filed on July 1, 2020. |
| 3.6 |
Certificate of Amendment to the Certificate of Incorporation of Astrotech Corporation. |
Exhibit 3.1 to Form 8-K filed on October 12, 2021. |
| 3.7 | Third Certificate of Amendment to the Certificate of Incorporation of Astrotech Corporation. | Exhibit 3.1 to Form 8-K filed on November 23, 2022. |
| 4.1 | Rights Agreement between the Company and American Stock Transfer & Trust Company, LLC, as Rights Agent, dated as of December 21, 2022. | Exhibit 4.1 to Form 8-K filed on December 21, 2022. |
| 4.2 | Amendment No. 1 to Rights Agreement dated as of December 18, 2023, to the Rights Agreement between the Company and Equiniti Trust Company, as Rights Agent, dated as of December 21, 2022. | Exhibit 4.2 to Form 8-K filed on December 18, 2023. |
| 4.3 |
Amendment No. 2 to Rights Agreement dated as of December 12, 2024, to the Rights Agreement between the Company and Equiniti Trust Company, as Rights Agent, dated as of December 21, 2022. | Exhibit 4.3 to Form 8-K filed on December 12, 2024. |
| 4.4 | Amendment No. 3 to Rights Agreement dated as of December 12, 2025, to the Rights Agreement between the Company and Equiniti Trust Company, as Rights Agent, dated as of December 21,2022. | Exhibit 4.4 to Form 8-K filed on December 17, 2025. |
| 10.1 | 1st Detect Corporation Transaction Incentive Bonus Plan. | Exhibit 10.1 to Form 8-K filed on October 19, 2026. |
| Exhibit No. |
Description |
Incorporation by Reference |
|
|
| 10.2 | First Amendment to the Astrotech Corporation Transaction Bonus Plan. | Exhibit 10.2 to Form 8-K filed on October 19, 2026. | ||
| 10.3 | Form of Award Letter to the 1st Detect Corporation Transaction Incentive Bonus Plan. | Exhibit 10.3 to Form 8-K filed on October 19, 2026. | ||
| 10.4 | Form of Award Letter to the Astrotech Corporation Transaction Bonus Plan. | Exhibit 10.4 to Form 8-K filed on October 19, 2026. | ||
| 31.1 |
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934. |
Filed herewith. |
|
|
| 31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934. | Filed herewith. | ||
| 32.1 |
Certification pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934. |
Filed herewith. | ||
| 101.INS |
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
Filed herewith. |
|
|
| 101.SCH |
Inline XBRL Taxonomy Extension Schema Document |
Filed herewith. |
|
|
| 101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
Filed herewith. |
|
|
| 101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase Document |
Filed herewith. | ||
| 101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase Document |
Filed herewith. |
|
|
| 101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
Filed herewith. |
|
|
| 104 |
The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, has been formatted in Inline XBRL. |
|||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Astrotech Corporation |
||
| Date: November 13, 2026 |
/s/ Thomas B. Pickens III |
|
| Thomas B. Pickens III | ||
| Chief Executive Officer, Chief Technology Officer, and Chairman of the Board (Principal Executive Officer and Principal Financial Officer)
|